Needham & Company reiterates a 'Buy' on Alnylam Pharmaceuticals (NASDAQ: ALNY), PT $16.

Needham analyst says, "Alnylam provided a corporate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE